舒尼替尼是一种口服可用的受体酪氨酸激酶抑制剂，可诱导急性髓性白血病细胞发生单核细胞分化，而1,25-二羟基维生素D3可增强这种分化。 - Suppr

Suppr

超能文献

Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3).

作者信息

Nishioka C, Ikezoe T, Yang J, Yokoyama A

出版信息

Leukemia. 2009 Nov;23(11):2171-3. doi: 10.1038/leu.2009.152. Epub 2009 Aug 6.

DOI:10.1038/leu.2009.152

PMID:19657366

Abstract

摘要

相似文献

Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3).舒尼替尼是一种口服可用的受体酪氨酸激酶抑制剂，可诱导急性髓性白血病细胞发生单核细胞分化，而1,25-二羟基维生素D3可增强这种分化。

Leukemia. 2009 Nov;23(11):2171-3. doi: 10.1038/leu.2009.152. Epub 2009 Aug 6.

1,25-Dihydroxyvitamin D3 induces monocytic differentiation of human myeloid leukemia cells by regulating C/EBPβ expression through MEF2C.1,25-二羟基维生素D3通过MEF2C调节C/EBPβ表达诱导人髓系白血病细胞单核细胞分化。

J Steroid Biochem Mol Biol. 2015 Apr;148:132-7. doi: 10.1016/j.jsbmb.2014.11.016. Epub 2014 Nov 20.

Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells.舒尼替尼诱导人急性髓系白血病 HL60 和 KG-1 细胞 G1 期细胞周期阻滞、分化和凋亡的效应机制。

Ann Hematol. 2013 Mar;92(3):301-13. doi: 10.1007/s00277-012-1627-7. Epub 2012 Nov 20.

Oncoprotein Cot1 represses kinase suppressors of Ras1/2 and 1,25-dihydroxyvitamin D3-induced differentiation of human acute myeloid leukemia cells.癌蛋白 Cot1 抑制 Ras1/2 和 1,25-二羟维生素 D3 诱导的人急性髓系白血病细胞分化的激酶抑制剂。

J Cell Physiol. 2011 May;226(5):1232-40. doi: 10.1002/jcp.22449.

Interplay between signalling pathways mediates 1,25alpha-dihydroxyvitamin D3-driven monocytic differentiation--JNKs are important.

Leuk Res. 2009 Oct;33(10):1298-300. doi: 10.1016/j.leukres.2009.03.023. Epub 2009 May 9.

Sunitinib: from rational design to clinical efficacy.舒尼替尼：从合理设计到临床疗效。

J Clin Oncol. 2007 Mar 1;25(7):884-96. doi: 10.1200/JCO.2006.06.3602.

Combination of 22-oxa-1,25-dihydroxyvitamin D(3), a vitamin D(3) derivative, with vitamin K(2) (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells.维生素D3衍生物22-氧杂-1,25-二羟基维生素D(3)与维生素K2（VK2）联合使用可协同增强HL-60细胞的细胞分化，但抑制VK2诱导的细胞凋亡。

Leukemia. 2002 Aug;16(8):1519-27. doi: 10.1038/sj.leu.2402614.

1,25-dihydroxyvitamin D3 primes acute promyelocytic cells for TPA-induced monocytic differentiation through both PKC and tyrosine phosphorylation cascades.1,25-二羟基维生素D3通过蛋白激酶C和酪氨酸磷酸化级联反应使急性早幼粒细胞对佛波酯诱导的单核细胞分化产生预适应。

Exp Cell Res. 1996 Jan 10;222(1):61-9. doi: 10.1006/excr.1996.0008.

1alpha,25-dihydroxyvitamin D3 and bryostatin-1 synergize to induce monocytic differentiation of NB4 acute promyelocytic leukemia cells by modulating cell cycle progression.1α,25-二羟基维生素D3与苔藓抑素-1协同作用，通过调节细胞周期进程诱导NB4急性早幼粒细胞白血病细胞向单核细胞分化。

Exp Cell Res. 2004 Mar 10;294(1):301-11. doi: 10.1016/j.yexcr.2003.11.013.

Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.阻断MEK/ERK信号通路可增强舒尼替尼对具有FLT3基因激活突变的白血病细胞的生长抑制作用及诱导凋亡作用。

Leuk Res. 2008 Jun;32(6):865-72. doi: 10.1016/j.leukres.2007.09.017. Epub 2007 Nov 5.

引用本文的文献

Exploring the Molecular Mechanism of 1,25(OH)D Reversal of Sorafenib Resistance in Hepatocellular Carcinoma Based on Network Pharmacology and Experimental Validation.基于网络药理学和实验验证探索1,25(OH)D逆转肝癌中索拉非尼耐药的分子机制

Curr Issues Mol Biol. 2025 Apr 29;47(5):319. doi: 10.3390/cimb47050319.

Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents.通过优化化疗药物和免疫调节剂的共递送实现癌症免疫化疗的改进。

Mol Pharm. 2018 Nov 5;15(11):5162-5173. doi: 10.1021/acs.molpharmaceut.8b00717. Epub 2018 Sep 28.

Effects of 1,25(OH)₂D₃ on Cancer Cells and Potential Applications in Combination with Established and Putative Anti-Cancer Agents.1,25-二羟维生素D₃对癌细胞的影响及其与已确立和潜在抗癌药物联合应用的潜力。

Nutrients. 2017 Jan 23;9(1):87. doi: 10.3390/nu9010087.

CSF-1R up-regulation is associated with response to pharmacotherapy targeting tyrosine kinase activity in AML cell lines.CSF-1R 的上调与针对 AML 细胞系中酪氨酸激酶活性的药物治疗反应相关。

Anticancer Res. 2012 Mar;32(3):893-9.

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.靶向 PIM 激酶增强舒尼替尼在肾细胞癌中的活性。

Br J Cancer. 2011 Nov 8;105(10):1563-73. doi: 10.1038/bjc.2011.426. Epub 2011 Oct 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验